Company
Tissue Regenix Group PLC
LON:TRX
Tissue Regenix Group PLC is a pioneering, international medical technology company, focusing on the development of regenerative products utilising its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. The company is currently helping to transform the treatment of patients in key surgical applications: biosurgery, orthopaedics (sports medicine/spine), dental, general, plastic surgery, urology/gynaecology, ophthalmology and cardiac.
255 stories · page 1 of 3
Tissue Regenix at a turning point
The company has two products spanning wound care, orthopaedics and cardiac applications which are based on two proven technologies
Tissue Regenix inks German distribution deal
The company has negotiated a multi-year agreement with Hamburg-based 2med
Tissue Regenix on course for underlying profitability in Q4, says research house
The latest update from Hardman & Co lifts the lid on the progress of the regenerative medicines specialist
Tissue Regenix says first-half losses narrow on sales growth, cost management
Revenue for the company's BioRinse division jumped 32% to US$7.8mln
Tissue Regenix: Four-pronged strategy helping deliver on growth aspirations
If March’s prelims from Tissue Regenix (TRX) marked an inflexion point for the regenerative medical devices specialist, then it was largely missed by the wider investing public
Tissue Regenix 'well-positioned to deliver persistently strong sales growth', says analyst
Hardman's Dr Martin Hall provided a brief appraisal of prospects after the company's trading statement
Tissue Regenix confident of meeting full-year expectations after solid first half
The regenerative medical devices specialist said sales to June 30 were around US$11.8mln, up 25% year on year, or 27% at constant currencies
Tissue Regenix 'on a pathway to sustainability'
"Progress is forecast to continue in 2022, resulting in 22% sales growth, which will drive margin expansion towards profitability by the end of 2022," Hardman said.
Tissue Regenix eyes profitability after a year of double-digit growth
"Our organisation continued to demonstrate success despite all the ongoing challenges associated with the pandemic,” said chief Daniel Lee
Tissue Regenix Group inks Italian distribution deal for OrthoPure XT product
It is teaming up with Geistlich Biomaterials Italia, which will help advance the clinical science supporting the OrthoPure
Tissue Regenix 2021 performance lives up to management expectations
It battled the twin challenges of Covid disruption and foreign exchange ‘headwinds’
Tissue Regenix encouraged by recovery in elective surgery
“Market indications for a post-pandemic recovery are encouraging”
Tissue Regenix launches two line extensions using breakthrough dCELL technology
The company is bringing to the market DermaPure Meshed and VNEWTM
Tissue Regenix completes phase one of San Antonio expansion on time and on budget
The company announced on 18 March it had completed the initial part of its expansion project; now the rest of the phase one expansion is done and dusted
Tissue Regenix confident on post-COVID-19 prospects
The capacity expansion programme will alleviate the supply issues that have previously hindered growth and will provide a step-change in the business trajectory, the firm said
Tissue Regenix says Texas expansion plans are on track
Work thus far has focused on relocating distribution operations and frozen tissue storage
Tissue Regenix highlights strong 2020 performance despite pandemic challenges
For the year to December 31, the regenerative medicine specialist said revenues for the year will be £12.8mln, in line with the prior-year figure despite the impact of the pandemic, adding that it also ended the period with a “strong cash p
Tissue Regenix announces appointment of David Cocke as its chief financial officer with immediate effect
Cocke has over 29 years of experience in the medical device industry holding senior finance and operations positions and In 1997, he founded NuPak Medical, an ISO-certified contract manufacturer of sterile disposable medical device
Tissue Regenix says it intends to appoint Brian Phillips and Trevor Phillips (no relation) as independent non-executive directors
Alongside these appointments, the group noted that, after many years of service, Alan Miller and Randeep Grewal have notified the board of their resignation as non-executive directors with immediate effect
Tissue Regenix hails significant milestone as it ships new product line to first customer
The delivery of initial orders for OrthoPure XT comes less than six months after regulatory sign-off and in the face of some stiff headwinds
Tissue Regenix appoints president of its US business as its new CEO
Danny Lee has been appointed to the board of the regenerative medical devices company “with immediate effect”
Tissue Regenix reports significantly reduced losses
The regenerative medicine group also highlighted strong demand for its products in the first half of its current year despite disruption from the coronavirus pandemic
Tissue Regenix secures first UK order for OrthoPure XT
It is expected that demand for this product line will increase in 2021 as additional distribution opportunities are identified
Tissue Regenix says head office and manufacturing switch will save an annualised £400,000
The company is making the short journey from Swillington to Garforth in Leeds
Tissue Regenix begins first phase of planned manufacturing capacity expansion
The increase in manufacturing capacity is needed to meet the burgeoning demand for the group's products, especially the BioRinse orthopaedic product portfolio
Tissue Regenix posts higher 2019 revenues, expects strong demand for product portfolio
The regenerative medicine specialist also saw its operating loss narrow to £7.2mln from £8.69mln in the prior year
Tissue Regenix receives CE mark for OrthoPure XT
The regenerative medicine firm said the CE mark permits the use of OrthoPure XT for the reconstruction of knee ligaments, including multi-ligament procedures following trauma
Tissue Regenix raises cash to expand manufacturing capacity in the US
“Not only do we expect this investment to provide the capacity required to scale our business and drive our commercial success, it will also increase the number of patients who can benefit from our broadened product portfolio" said Gareth J
Archive
San Leon's chief executive puts his hand in his pocket
A look at some of the major movers in London on Monday
Tissue Regenix develops new product line in collaboration with global healthcare giant
Tissue Regenix said it expects the newly developed product line will make a material contribution to its revenue growth over the next couple of years.
Tissue Regenix "cash runway" extended to August following additional US financial support
It has been given a further US$417,000 loan from the US government as part of the coronavirus support scheme
Tissue Regenix secures US government-backed loan to extend cash runway amid pandemic
The firm also reported that revenues for its first quarter have increased 18% year-on-year
Tissue Regenix encouraged by funding discussions which are continuing
Investors were told the regenerative medicines specialist hopes to tie a deal up in the "near future"
Tissue Regenix announces changing of the guard as chairman Samuel departs
John Samuel is stepping down after 12 years with the company
No evidence of data breach from cyber attack says Tissue Regenix
Any associated costs of the system restoration are unlikely to be material to short-term cash flow
Tissue Regenix hit by cybersecurity breach
The incident is not believed to have impacted its UK operations or financial systems.
Tissue Regenix says sales and earnings in-line; looking for additional sources of funding
The regenerative medicines specialist said it has £2.4mln of cash, including a £1mln revolving credit facility. This, it added, was enough to see it through to “at least the end of April”
Tissue Regenix appoints new finance boss
Kirsten Lund has been promoted to finance director for her "invaluable" knowledge and understanding of the business, after nine years at the firm
Tissue Regenix rejigs loan agreement
Chairman John Samuel: "I am very pleased that Midcap have shown their support for the company by entering this revised agreement"
Tissue Regenix optimistic about MidCap covenant talks
“These discussions are progressing well and the board is optimistic of being able to agree a solution with MidCap Financial"
Tissue Regenix confirms US$300,000 grant for San Antonio facility
The regenerative medicine company said the funds would help upgrade utilities and infrastructure at the site
Tissue Regenix develops product extension to be used in female pelvic medicine
Interim chief executive Gareth Jones said: “Our commercial success is predicated on our ability to identify new clinical applications and rapidly develop product lines to meet this demand."
Tissue Regenix's production capacity increases should bear fruit in the second half
During the first half, the regenerative medicines specialist streamlined its logistics network and enhanced its operational procedures
Tissue Regenix appoints interim finance chief Barker to full-time role
The regenerative medical devices specialist said Mike Barker will join the board with immediate effect having held the role on an interim basis since the start of the year
Tissue Regenix adds manufacturing capacity in US expansion push
“Having commenced a second shift at the beginning of the year in our current facility in San Antonio, the phased build out of this new facility will allow us to meet the growing requirements of our customers well into the future," said boss
Archive
Proactive news snapshot: Digitalbox, Seeing Machines, Alba Minerals Resources...
A glance at some of the day's highlights from the Proactive Investors newswire
Tissue Regenix chief executive steps down as illness recurs
John Samuel will resume as executive chairman until a full-time chief executive is appointed
Investments and investor services
Fund manager Randeep Grewal appointed new chairman of BB Healthcare
Justin Stebbing is stepping down after three years in the role, and Randeep Grewal has been appointed as his successor with immediate effect
Archive
Proactive news snapshot: Active Energy, Be Heard Group, EQTEC, Horizonte Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Tissue Regenix secures US$20mln credit facility; says current trading is in line
“The additional capital secured through the credit facilities allows us to focus on further scaling the manufacturing capacity of the business and pursue further partnership opportunities, driving the business trajectory towards self-sustai
Investments and investor services
Cellcast downcast as Kenya ups the ante in attack on the gambling industry
A look at the day's major movers, including Topps Tiles, Mortgage Advice, Shoe Zone, Knight's Group, UDG, GYG and Galliford Try.
Archive
Proactive news snapshot: VR Education, IronRidge Resources, Sirius Minerals, Itaconix …
A glance at some of the day's highlights from the Proactive Investors newswire
Tissue Regenix boss to return to full-time duties in June
Steve Couldwell has been out of action so far this year while he undergoes medical treatment
Investments and investor services
Andalas subsides after finance director resigns
A look at the day's major movers, including Gordon Dadds, Motif Bio, Proton Power, Regal Petroleum, Saga and Xeros Technology
Archive
Proactive news snapshot: ReNeuron Group PLC, Tissue Regenix Group PLC, ANGLE PLC, Motif Bio PLC …
A glance at some of the day's highlights from the Proactive Investors newswire
Tissue Regenix secures additional coverage for DermaPure from a US Group Purchasing Organization
The AIM-listed firm said the additional coverage will open up access to a further 1,500 hospitals and 32,500 alternative care providers, primarily in the South Eastern region of the US
Investments and investor services
FTSE 100 closes in positive territory, boosted by better-than-expected US March jobs figures as Brexit uncertainty continues
Mid-cap cousin FTSE 250 was also lower, shedding around 56 points at 19,507
Tissue Regenix continues regeneration as it targets breaking even by 2020
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier